A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy

Inclusion Criteria: * Adult patients, 18-70 years of age * Patients with either unresectable Stage IIIc or IV BRAFV600 mutation-positive metastatic melanoma or other malignant BRAFV600 mutation-positive tumor type and who have no acceptable standard treatment options * Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2 * Full recovery from any major surgery or significant traumatic injury at least 14 days prior to the first dose of study treatment * Adequate hematologic and end organ function * Female patients of childbearing potential and male patients with female partners of childbearing potential must agree to use 2 effective methods of contraception as defined by protocol during the course of the study and for at least 6 months after completion of study treatment Exclusion Criteria: * Prior treatment with vemurafenib or other BRAF inhibitor within 42 days of Day 1 * Prior anti-cancer therapy within 28 days (6 weeks for nitrosureas or mitocyn C, or 14 days for hormonal therapy or kinase inhibitors) before the first dose of study treatment Day 1 * Palliative radiotherapy within 2 weeks prior to first dose of study treatment Day 1 * Experimental therapy within 4 weeks prior to first dose of study treatment Day 1 * History of clinically significant cardiac or pulmonary dysfunction, including current uncontrolled Grade \>/=2 hypertension or unstable angina * Current Grade \>/=2 dyspnea or hypoxia or need for oxygen supplementation * History of myocardial infarction within 6 months prior to first dose of study treatment * Active central nervous system lesions (i.e. participants with radiographically unstable, symptomatic lesions) * History of bleeding or coagulation disorders * Allergy or hypersensitivity to vemurafenib or acenocoumarol formulations * History of malabsorption or other condition that would interfere with the enteral absorption of study treatment * Participants with VKORC1 mutations (1639G\→A, 1173C\→T) in either one allele (heterozygous)or two alleles (homozygous) * Participants with CYP2C9\*3 mutations in either one allele (heterozygous) or two alleles (homozygous) * History of clinically significant liver disease (including cirrhosis), current alcohol abuse, or active hepatitis B or hepatitis C virus infection * Human immunodeficiency virus (HIV) infection requiring antiretroviral treatment, or AIDS-related illness * Pregnant or lactating women